Antitrust risk-shifting provisions in Myriad Genetics, Inc./Crescendo Bioscience, Inc. merger agreement | Practical Law

Antitrust risk-shifting provisions in Myriad Genetics, Inc./Crescendo Bioscience, Inc. merger agreement | Practical Law

Antitrust risk-shifting provisions in Myriad Genetics, Inc./Crescendo Bioscience, Inc. merger agreement

Antitrust risk-shifting provisions in Myriad Genetics, Inc./Crescendo Bioscience, Inc. merger agreement

February 02, 2014 • Antitrust Risk-shifting • $270 million (subject to purchase price adjustment).
End of Document

© 2024 Thomson Reuters. No claim to original U.S. Government Works.